Cargando…
Prognostic studies in patients with high-risk primary breast cancer (HRPBC) receiving high-dose chemotherapy (HDC)
Autor principal: | Nieto, Y |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231906/ http://dx.doi.org/10.1186/bcr1226 |
Ejemplares similares
-
Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: update of the Dutch randomized trial
por: Rodenhuis, S, et al.
Publicado: (2005) -
SOLTI (Solid Tumor Intensification) Group experience with high-dose chemotherapy treatment for early breast carcinoma
por: Funes, H Cortés, et al.
Publicado: (2005) -
On-site audits of the two clinical trials reported from South Africa involving high-dose chemotherapy (HDC) therapy for breast cancer
por: Weiss, RB, et al.
Publicado: (2001) -
ML-12 HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION (HDC-ASCT) FOR THE PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
por: Miyakita, Yasuji, et al.
Publicado: (2022) -
Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance
por: Manso, Luis, et al.
Publicado: (2016)